Why the study?
Aspirin is widely used for secondary prevention, but reports have emerged regarding aspirin resistance or high on-treatment platelet reactivity.
Does high on-treatment platelet reactivity to aspirin affect clinical endpoints in patients after myocardial infarction?
Does high on-treatment platelet reactivity to aspirin affect clinical endpoints in patients after myocardial infarction?
A high proportion of post-myocardial infarction patients develop high on-treatment platelet reactivity to aspirin during long-term follow-up, but this may not translate to an increased risk of clinical coronary endpoints.
Answers are grounded in this paper and cite their sources.
HTPR to ASA may flag higher long-term risk post-MI; leaves open whether platelet testing should guide therapy.
Aspirin (ASA) is widely used as an antiplatelet therapeutic drug in secondary prevention. Last years brought many reports on ASA resistance or high on-treatment platelet reactivity (HTPR) to aspirin.This study is a post-hoc prospective analysis with 30 patients evaluated during follow up on average of 6.3 years after hospitalization from myocardial infarction. The examined population was divided into two subgroups according to the response to ASA. In order to estimate the function of blood platelets and their responsiveness to acetylsalicylic acid therapy, ASPI-test was used. The measurements were performed by the method of whole blood impedance aggregometry. During long-term follow up significantly higher percentage of high platelet reactivity was observed, compared with previous visits (p = 0.00001). Considering clinical endpoints of the research that were connected with coronary disease, no differences were obtained.The frequency of HTPR to aspirin in this study was higher than data reported in literature among subjects with CV diseases. In long-term observation the highest percentage of ASA non-responders was reported (58.6%). HTPR to aspirin did not affect the presence of the clinical endpoints for the study.
No takes yet. Share an insight, caveat, or question.
Stolarek et al. (2022) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: